Search research articles
Contact Us
Filters
Showing results (1-10 of 86) with videos related to
Page
of 9
Sort By:
Current Opinion in Rheumatology
|
April 15, 2009
Recent concepts in the inhibition of radiographic progression with biologics
Edward Keystone
Arthritis Research & Therapy
|
June 18, 2005
B cell targeted therapies
Edward Keystone
The Journal of Rheumatology. Supplement
|
November 7, 2007
Optimizing treatment with biologics
Reuven Mader, Edward Keystone
Rheumatic Diseases Clinics of North America
|
June 3, 2004
Adalimumab therapy in rheumatoid arthritis
Edward Keystone, Boulos Haraoui
Current Opinion in Rheumatology
|
December 14, 2005
Musculoskeletal manifestations and autoimmune diseases related to new biologic agents
Boulos Haraoui, Edward Keystone
Rheumatology and Therapy
|
October 18, 2016
Rituximab for Rheumatoid Arthritis
Marc D Cohen, Edward Keystone
Current Rheumatology Reports
|
August 20, 2013
Cell-signaling therapy in rheumatoid arthritis
Edward Keystone, Marc D Cohen
Expert Opinion on Biological Therapy
|
July 11, 2015
Subcutaneous abatacept in rheumatoid arthritis: current update
Edward Keystone, Abdulaziz Alkhalaf, Mosaab Makkawy
Arthritis and Rheumatism
|
October 4, 2005
Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?
Josef S Smolen, Daniel Aletaha, Edward Keystone
Rheumatology (Oxford, England)
|
February 26, 2010
Is a 12-week trial sufficient to evaluate clinical responses to etanercept or MTX treatment in early RA?
Arthur Kavanaugh, Edward Keystone, JingYuan Feng, et al.
Page
of 9
Search research articles
Search
Showing results (1-10 of 86) with videos related to
Sort By:
Page
of 9
Current Opinion in Rheumatology
|
April 15, 2009
Recent concepts in the inhibition of radiographic progression with biologics
Edward Keystone
Arthritis Research & Therapy
|
June 18, 2005
B cell targeted therapies
Edward Keystone
The Journal of Rheumatology. Supplement
|
November 7, 2007
Optimizing treatment with biologics
Reuven Mader, Edward Keystone
Rheumatic Diseases Clinics of North America
|
June 3, 2004
Adalimumab therapy in rheumatoid arthritis
Edward Keystone, Boulos Haraoui
Current Opinion in Rheumatology
|
December 14, 2005
Musculoskeletal manifestations and autoimmune diseases related to new biologic agents
Boulos Haraoui, Edward Keystone
Rheumatology and Therapy
|
October 18, 2016
Rituximab for Rheumatoid Arthritis
Marc D Cohen, Edward Keystone
Current Rheumatology Reports
|
August 20, 2013
Cell-signaling therapy in rheumatoid arthritis
Edward Keystone, Marc D Cohen
Expert Opinion on Biological Therapy
|
July 11, 2015
Subcutaneous abatacept in rheumatoid arthritis: current update
Edward Keystone, Abdulaziz Alkhalaf, Mosaab Makkawy
Arthritis and Rheumatism
|
October 4, 2005
Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?
Josef S Smolen, Daniel Aletaha, Edward Keystone
Rheumatology (Oxford, England)
|
February 26, 2010
Is a 12-week trial sufficient to evaluate clinical responses to etanercept or MTX treatment in early RA?
Arthur Kavanaugh, Edward Keystone, JingYuan Feng, et al.
Page
of 9